Merck: to study drug combo to treat cervical cancer
(CercleFinance.com) - Singapore-based biotech firm Tessa said on Tuesday that it would collaborate with US industry heavyweight Merck to test a combination of drugs for the treatment of cervical cancer.
Under the agreement, Tessa will conduct a multi-center Phase 1b/2 trial to evaluate the safety and efficacy of the combination of Tessa's therapy TT12 and Merck's immunotherapy Keytruda in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.
The trial is planned to be conducted in the United States, Singapore and South Korea, Tessa said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Under the agreement, Tessa will conduct a multi-center Phase 1b/2 trial to evaluate the safety and efficacy of the combination of Tessa's therapy TT12 and Merck's immunotherapy Keytruda in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.
The trial is planned to be conducted in the United States, Singapore and South Korea, Tessa said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.